The multidisciplinary management of HER2-positive breast cancer brain metastases: from new biological insights to future therapeutic options
2024

Managing Brain Metastases in HER2-Positive Breast Cancer

publication Evidence: moderate

Author Information

Author(s): Claudia von Arx, Claudia Calderaio, Alessandra Calabrese, Benedetta Marciano, Claudia Martinelli, Vincenzo Di Lauro, Ivana Cerillo, Daniela Cianniello, Michelino De Laurentiis

Primary Institution: Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy

Hypothesis

What are the current and future treatment strategies for HER2-positive breast cancer brain metastases?

Conclusion

The review highlights the need for multidisciplinary approaches to improve outcomes for patients with HER2-positive breast cancer brain metastases.

Supporting Evidence

  • HER2-positive breast cancer patients with brain metastases have worse survival outcomes compared to those with metastases outside the brain.
  • New drugs have shown strong efficacy in controlling brain metastases in HER2-positive breast cancer.
  • Multidisciplinary management is essential for optimizing treatment strategies for brain metastases.

Takeaway

This study talks about how doctors can better treat patients with brain cancer that started from breast cancer, especially those with a specific type called HER2-positive.

Methodology

This is a review article discussing various treatment strategies and future directions for managing brain metastases in HER2-positive breast cancer.

Limitations

The review is based on existing literature and may not cover all recent developments in the field.

Digital Object Identifier (DOI)

10.3389/fonc.2024.1447508

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication